Optimi Health Corp.
Optimi Health Corp. is a Canada-based pharmaceutical manufacturer focused on GMP-grade psychedelic drug products, including botanical psilocybin and MDMA-based formulations. The company produces active pharmaceutical ingredients and finished dosage forms at its own licensed facility in British Columbia and supplies regulated clinical and therapeutic programs in international markets.
Business
Share of revenueValidated psilocybin-based drug products made for regulated therapeutic and research use.
GMP-grade MDMA products supplied for clinical research and special access programs.
In-house produced APIs used as inputs for finished psychedelic drug products.
Encapsulated, packaged drug products prepared for regulated patient access and trials.
Licensed GMP manufacturing, formulation, and export support for clinical customers.
Customers
Optimi sells to regulated clinical and therapeutic programs rather than broad consumer markets. Its buyers include clinical research organizations, special access program users, and healthcare channels that require GMP-grade psychedelic products with documented quality and traceability. The company also serves patients in jurisdictions where authorized-prescriber or special-access pathways allow use of these drugs.
Buy psilocybin and MDMA supply for controlled clinical trials and research protocols.
Buy finished products for patients who can access psychedelic therapies through regulated pathways.
Use supplied drug products for prescribed treatment under country-specific access schemes.
Source GMP-grade dosage forms and APIs for supervised mental health treatment settings.
Strategy
Optimi’s strategy is built around controlling the full production chain, from cultivation and extraction through formulation, capsule filling, packaging, and export. That vertical integration supports both commercial supply and clinical-trial supply from the same GMP facility, which is important in a market where regulated production capability is a key barrier to entry. The company is also focused on expanding into additional regulated jurisdictions while maintaining licensed, traceable manufacturing.
A controlled manufacturing platform is the core competitive asset in psychedelic pharma.
Growth depends on approvals and access pathways in multiple countries.
Dual-use manufacturing can improve facility utilization and customer reach.
Geography
Optimi manufactures in Princeton, British Columbia, Canada, where its licensed GMP facility and in-house production chain are located. The company sells into regulated markets internationally, with reported patient access in Australia and Canada and an initial shipment into the United Kingdom. Its business is therefore shaped by cross-border pharmaceutical regulation, import/export controls, and country-specific access pathways.
Risks
Optimi depends on highly regulated access pathways, so demand can shift with changes in national health rules, import controls, and prescribing frameworks. The business also faces execution risk around GMP quality, product consistency, and scaling a specialized manufacturing model across multiple countries. As a psychedelic-drug supplier, it is exposed to the broader uncertainty of a still-developing therapeutic market and the possibility that clinical adoption progresses more slowly than expected.
- Regulatory dependencyImpact: HighLikelihood: High
Sales depend on special-access, prescribing, and clinical-trial rules in each jurisdiction.
Exposure - GMP quality and manufacturing complianceImpact: HighLikelihood: Medium
The business model relies on producing validated pharmaceutical products in-house.
Exposure: Licensed facility operations in British Columbia
- Market adoption riskImpact: MediumLikelihood: Medium
Psychedelic therapies are still an emerging treatment category with evolving acceptance.
Exposure: Clinical and patient-access channels
- Cross-border logisticsImpact: MediumLikelihood: Medium
Finished drug products and APIs must move across borders under controlled conditions.
Exposure: International shipments
Accounting
Judgemental itemsManagement must assess whether the company can continue for at least 12 months.
Impact: Can affect valuation, disclosure, and financial statement presentation
Licensed pharmaceutical operations can create uncertain obligations and reserves.
Impact: May change liabilities and period expenses
Results include Optimi Labs Inc. and Optimi Nutraceuticals Corp.
Impact: Affects reported assets, liabilities, and operating results
Certain financial instruments are measured at fair value under IFRS.
Impact: Can create non-cash gains or losses in profit or loss
Similar listed companies
Publicly listed companies with a comparable business focus.
Psyence Biomedical Ltd
PBMWW · Pharmaceutical Preparations
Definium Therapeutics, Inc.
DFTX · Medicinal Chemicals & Botanical Products
XTL Biopharmaceuticals Ltd
XTLB · Pharmaceutical Preparations
Pluri Inc.
PLUR · Biological Products, (No Diagnostic Substances)
Organigram Global Inc
OGI · Pharmaceutical Preparations
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
Last updated: 28/09/2026